Decreased levels of liver-expressed antimicrobial peptide-2 and ghrelin are related to insulin resistance in women with polycystic ovary syndrome

Basit Öğe Kaydı
dc.authoridalan, murat/0000-0002-9108-2990
dc.authorwosidalan, murat/AAH-8813-2020
dc.authorwosidaslnaipour, behnaz/AAD-6053-2021
dc.contributor.authorAslanipour, Behnaz
dc.contributor.authorAlan, Murat
dc.contributor.authorDemir, Ismail
dc.date.accessioned2023-01-12T19:59:31Z
dc.date.available2023-01-12T19:59:31Z
dc.date.issued2020
dc.departmentN/A/Departmenten_US
dc.description.abstractLiver-expressed antimicrobial peptide 2 (LEAP-2) is a newly identified peptide hormone involved in glucose metabolism. It acts as a noncompetitive antagonist of ghrelin hormone's receptor. Polycystic ovary syndrome (PCOS) is a common metabolic and reproductive disease associated with insulin resistance. We aimed to compare circulating LEAP-2 levels in subjects with PCOS and controls. We also focused to determine whether there was a relationship between LEAP-2 and metabolic parameters in women with PCOS. We enrolled 64 subjects with PCOS and 64 age and body mass index (BMI)-matched controls into the current cross-sectional study. Circulating LEAP-2 and ghrelin levels were measured via ELISA method. Metabolic and hormonal parameters of the involved subjects were analyzed. We found that circulating LEAP-2 and ghrelin levels were decreased in women with PCOS as compared with controls. LEAP-2 showed a positively independent association with ghrelin while LEAP-2 exhibited an inverse association with insulin resistance, BMI, and free-androgen index (FAI). Additionally, subjects having the lowest tertile of LEAP-2 were in positive link of developing PCOS risk with respect to those subjects having the highest tertile of LEAP-2 levels. Decreased LEAP-2 levels were associated with a high possibility of having PCOS risk associated with insulin resistance.en_US
dc.identifier.doi10.1080/09513590.2019.1665646
dc.identifier.endpage225en_US
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue3en_US
dc.identifier.pmid31526069en_US
dc.identifier.startpage222en_US
dc.identifier.urihttps://doi.org/10.1080/09513590.2019.1665646
dc.identifier.urihttps://hdl.handle.net/11454/77185
dc.identifier.volume36en_US
dc.identifier.wosWOS:000486836800001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofGynecological Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPolycystic ovary syndromeen_US
dc.subjectLEAP-2en_US
dc.subjectghrelinen_US
dc.subjectinsulin resistanceen_US
dc.subjectbody mass indexen_US
dc.subjectGrowthen_US
dc.subjectPrevalenceen_US
dc.titleDecreased levels of liver-expressed antimicrobial peptide-2 and ghrelin are related to insulin resistance in women with polycystic ovary syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu